Free Zones in Iran: What They Can and Cannot Save

1. Key takeaways

Iran’s free trade zones and special economic zones offer preferential arrangements on customs duties and taxes, but GRZAN’s judgment is that what a free zone can save is the tax at the import stage, and what it cannot save is the compliance for product access. For a medical device to be sold in the Iranian mainland market, IFDA registration, the IRC and identification code registration must all still be completed. Treating the free zone as a channel for bypassing registration is a common strategic misjudgement. The two tracks are legally distinct: the zone regime governs taxation and customs treatment of goods within the zone, while the market access regime governs whether a device may lawfully be sold to end users in the mainland. Once goods move from the zone into the mainland market for sale, the corresponding taxes must be paid back under mainland rules — which is why a cost model built on a zero-tax assumption collapses precisely when the business starts to scale. GRZAN’s recommendation is to decide the sales territory first, and only then decide whether a free zone has a role; for mainland-facing projects the zone’s realistic value lies mainly in logistics, warehousing and regional distribution rather than in tax savings.

• Free zones and special economic zones offer tax and customs preferences, with duration and scope varying by zone and by policy.
• What the zone saves is the tax at the import stage; product access compliance cannot be saved.
• Mainland sales still require IFDA registration, the IRC and identification code registration.
• Moving goods from a zone into the mainland market triggers back-payment of the corresponding taxes under mainland rules.
• Zones suit re-export trade, regional distribution and supply to medical institutions inside the zone; for mainland end sales their value is mainly logistics and warehousing.

2. Legal basis

The boundary between what a zone can and cannot save rests on the VAT treatment of imported goods, on the zone-specific preference arrangements, and on the approval requirement for domestic sales in the 1955 law. The items below state each basis and its verification status.

1. VAT Law (approved 23 May 2021, effective 3 January 2022): imported goods are levied VAT by customs at release on customs value plus customs duty; the standard rate is 9%.
2. Zone arrangements: Iran’s free zones and special economic zones provide preferential tax arrangements for economic activity, with the specific duration and scope varying by zone and by policy — this is a practical estimate, and the current rules published by each zone’s administration govern.
3. Law on Regulation of Medical, Pharmaceutical and Food and Beverage Affairs, FAOLEX LEX-FAOC227692, dated 20 June 1955, Article 3 (domestic sales require approval).

3. Expert insights

Insight 1: the zone solves tax, and registration solves access — they are different legal tracks. Goods inside a free zone can enjoy customs and tax preferences, but the moment they enter the mainland market for sale, the import and access procedures are triggered. No quantity of zone paperwork substitutes for the registration certificate, the IRC and identification code registration, because the authorities that control mainland sales are the authorities that administer those instruments. Companies that conflate the two tracks typically discover the gap at the point of sale rather than at the point of import — the most expensive place to discover it, because inventory, customer commitments and channel agreements have all been built by then on an assumption the law does not support.

Insight 2: the back-payment logic should be modelled in advance. When goods move from a free zone into the mainland market, the corresponding taxes must be paid back under mainland rules. If the early cost model was built on a zero-tax assumption, the later back-payment directly erodes gross margin, and it does so on the sales that were supposed to be the most profitable. The corrective is to include the zone-to-mainland back-tax in the cost model from the first version, so that the business case reflects the true landed cost of every mainland sale rather than an idealised one.

Insight 3: the free zone fits specific business models. Re-export trade, regional distribution, and supply to medical institutions located inside the zone are the scenarios where the zone model genuinely applies. For end sales into the Iranian mainland, the value of the zone is mainly in logistics and warehousing — faster inventory positioning, consolidated storage, regional buffering — rather than in tax advantages. Framing the zone decision around the actual business model, instead of around headline tax rates, is what prevents a structurally sound zone setup from being attached to the wrong commercial plan. The same physical setup can be an asset for a distribution business and a liability for a mainland sales business, so the decision belongs to the commercial strategy discussion, not to the tax discussion alone.

4. Practical recommendations

• Decide the sales territory first, then whether to use a zone: for projects selling into the mainland, do not build the tax planning around the free zone.
• Model the back-tax cost: include the zone-to-mainland back-payment in the cost model instead of assuming a zero tax burden.
• Verify the current zone rules: confirm the preference duration and applicable scope with the administration of the specific zone.
• Evaluate the warehousing and logistics value separately: even where the tax advantage is limited, the warehousing and distribution value of the zone may still stand on its own.

5. Verification checklist

• □ The end-sales territory has been defined (inside the free zone versus the mainland)
• □ The zone-to-mainland back-tax cost has been included in the cost model
• □ The current preference rules have been verified with the administration of the specific zone
• □ Mainland sales projects have confirmed that IFDA registration and obtaining the IRC are still required
• □ The warehousing and distribution value has been assessed separately

Regulatory information verified as of 29 October 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Iranian market. Our team coordinates local import arrangements, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com